Lazertinib mesylate - CAS 2247995-37-3

Lazertinib (mesylate) (YH25448 (mesylate) ; GNS-1480 (mesylate) ) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.

Akt, ERK, EGFR

MAPK, JAK/STAT signaling, Cytoskeletal Signaling, Angiogenesis, PI3K/Akt/mTOR signaling, Tyrosine Kinase/Adaptors

2247955

C31H38N8O6S

650.75

O=C(C=C)NC1=CC(NC2=NC=CC(=N2)N3N=C(C=4C=CC=CC4)C(=C3)CN(C)C)=C(OC)C=C1N5CCOCC5.O=S(=O)(O)C

-20°C

Ice Packs

Small Compound